J Korean Diabetes > Volume 13(1); 2012 > Article
The Journal of Korean Diabetes 2012;13(1):1-6.
DOI: https://doi.org/10.4093/jkd.2012.13.1.1    Published online March 31, 2012.
혈당 조절지표로의 당화알부민과 1,5-Anhydroglucitol (1,5-AG)
김원준, 박철영
Review of the Potential Glycemic Markers Glycated Albumin and 1,5-anhydroglucitol.
Won Jun Kim, Cheol Young Park
1Department of Endocrinology and Metabolism, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
2Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. cydoctor@chol.com
The measure of HbA1c is the gold standard index of glycemic control in clinical practice for diabetes treatment and is well known as a risk marker for diabetes complications. However, HbA1C does not accurately reflect glucose fluctuations or the actual status of glycemic control for several days or weeks. HbA1c measurement can be confounded in the anemia, hemoglobinopathy, or renal impairment. In comparison, glycated albumin (GA), a ketoamine formed by binding of albumin and glucose, more accurately reflects short-term changes in plasma glucose and postprandial plasma hyperglycemia (PPH). GA is not affected by hemoglobin or dialysis. 1,5-Anhydroglucitol (1,5-AG), another glycemic marker, structurally resembles glucose and decreases with spikes of hyperglycemia exceeding the average renal threshold for glucose. Especially, 1,5-AG level is reflective of PPH or glycemic variability and becomes an increasingly important contributor in a moderately controlled glycemic state, even when HbA1c level is within the target range. Herein, the usefulness of and recent studies on GA and 1,5-AG are summarized. Further investigations about the associations between these glycemic markers and diabetes complications are needed.
Key Words: Glycosylated hemoglobin A, Glycosylated serum albumin, 1,5-anhydroglucitol, Diabetes mellitus
METRICS Graph View
  • 7 Crossref
  •  0 Scopus
  • 1,550 View
  • 12 Download
Related articles

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2023 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer